Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, has recently been included in the FTSE Russell Global Equity Index Series.

FTSE Russell is a globally renowned index provider, whose index products cover markets in more than 70 countries and regions, with approximately $20 trillion in assets benchmarked against FTSE Russell index products.

Hu Huiguo, Director, Senior Vice President, and Board Secretary of Mabwell, said: “Being included in the FTSE Russell Global Equity Index Series indicates market's ongoing recognition of Mabwell's operational performance, stock liquidity, and development potential. Mabwell will continue to commit to the research and commercialization of innovative drugs, and actively promote the globalization of the value of innovative products, benefiting more patients worldwide, thereby realizing the potential and goals for long-term sustainable growth, and creating more value for shareholders and society.”